Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

85.47B

Market cap85.47B

Price-Earnings ratio

20.61

Price-Earnings ratio20.61

Dividend yield

0.44%

Dividend yield0.44%

Average volume

731.77K

Average volume731.77K

High today

$835.38

High today$835.38

Low today

$830.12

Low today$830.12

Open price

$835.38

Open price$835.38

Volume

10.86K

Volume10.86K

52 Week high

$847.00

52 Week high$847.00

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 85.47B, Regeneron(REGN) trades at $830.12. The stock has a price-to-earnings ratio of 20.61 and currently yields dividends of 0.44%.

As of 2026-08-24, Regeneron(REGN) stock has fluctuated between $830.12 and $835.38. The current price stands at $830.12, placing the stock 0.0% above today's low and -0.6% off the high.

Regeneron(REGN) shares are trading with a volume of 10.86K, against a daily average of 731.77K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $847.00 at its peak.

REGN News

Simply Wall St 1d

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals?

Earlier this week, Regeneron Pharmaceuticals announced that the FDA approved Pasatru (garetosmab-grts), a monthly intravenous monoclonal antibody, to reduce new...

Simply Wall St 3d

Regeneron Pharmaceuticals Wins Pasatru Approval, Is The Upside Already Priced In?

Regeneron Pharmaceuticals (REGN) stock moved after the U.S. Food and Drug Administration approved Pasatru for adults with fibrodysplasia ossificans progressiva....

TipRanks 3d

Regeneron Stock Buckling as Shareholders Sue Over Cancer Drug Claims

A class action lawsuit was filed against biotechnology company Regeneron (REGN) on July 16, which could put further pressure on its troubled share price. The pl...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

More REGN News

Simply Wall St 4d

Regeneron Pharmaceuticals Wins FDA Approval For The First Adult FOP Treatment

Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru (garetosmab-grts) as the first treatment for adults with fibrodysplasia ossificans...

TipRanks 4d

Regeneron’s Pasatru granted FDA approval for FOP

The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups in adults with...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.